María Molina‐Molina

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Toby M. Maher, Tamera J. Corte, Aryeh Fischer et al. · The Lancet Respiratory Medicine · 2019 · 606 citations

Antifibrotic Therapy, Advanced Lung Disease, Pulmonary Fibrosis +3

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis

Richard J. Allen, Beatriz Guillén‐Guío, Justin M. Oldham et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 323 citations · Full text

Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study

Thomas M Drake, Annemarie B Docherty, Ewen M. Harrison et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 228 citations · Full text

Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis

Xiaopeng Li, María Molina‐Molina, Amal Abdul‐Hafez et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2008 · 183 citations

Experimental Lung Fibrosis, Inflammatory Lung Disease, Lung Inflammation +18